ClinicalTrials.gg
Not yet recruitingNCT07739888LILAC-TIMI 76Updated Jul 31, 2026

Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

A Phase 3 interventional study of Abelacimab in Atrial Fibrillation (AF), sponsored by Novartis Pharmaceuticals. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,500
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in eligible patients who completed the double-blinded core part of CMAA868A2302 (ANT-010/NCT05712200)

Read the detailed description

Patients who provide consent, will need to complete the end of treatment visit (EoT) assessments of the Core Part of CMAA868A2302 (ANT-010/NCT05712200) prior to receiving first dose in the OLE. Day 1 visit or dosing should occur on same day as EoT visit to avoid treatment interruption.

Participation in OLE will end if a patient permanently discontinues study treatment, or the study is completed or terminated by the Sponsor.

All patients will need to complete End of Study in Extension visit in person followed by a phone call visit 30 days after End of Extension visit. Any updates in AE or concomitant medications will be reported by a phone call/video call visit.

02

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • abelacimab
  • randomized
  • placebo-controlled
  • double-blind
  • endpoint evaluation
  • atrial fibrillation
03

In context

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients are able to provide written to enter the extension part.
  • Patients must be on study treatment at the time of EoT visit in the core part.

Exclusion criteria

Exclusion Criteria:

  • Patients meeting any exclusion criteria in the core part.
  • Patients who have a history or evidence of any disorder, condition, or disease that in the investigator's opinion or Sponsor physician (if consulted), would put the participant at risk or interfere with the study participation
  • History of to the study drug or its , to drugs of similar chemical classes
  • Any medical or psychiatric condition which in the judgment of the Investigator either requires urgent medical intervention/hospitalization or may preclude patients from complying with study requirements for the duration of the study.

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    Abelacimab (MAA868)

    abelacimab 150 mg subcutaneous (SC)

    Biological: Abelacimab

Interventions

  • BiologicalAbelacimab

    Abelacimab provided as liquid in vial (150 mg/mL)

    Also known as: MAA868

06

What researchers measure

Primary outcomes

  1. Time to first ISTH major Bleeding events

    Time to first International Society on Thrombosis and Haemostasis (ISTH) major bleeding events

    Time frame: Up to 3 years

  2. Time to first BARC type 3c/5 bleeding

    Time to first Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding

    Time frame: Up to 3 years

  3. Number of participants with ISTH major or CRNM bleeding

    Number of participants with International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant non-major (CRNM) bleeding

    Time frame: Up to 3 years

  4. Number of participants with bleeding

    All suspected bleeding events either reported by the patient or observed by the Investigator

    Time frame: Up to 3 years

  5. Number of participants with TEAEs and TESAEs

    Number of participants with treatment emergent AEs (TEAEs) and treatment emergent SAEs (TESAEs)

    Time frame: Up to 3 years

  6. Number of participants with treatment discontinuations due to TEAEs

    Number of participants with treatment discontinuations due to treatment emergent AEs (TEAEs)

    Time frame: Up to 3 years

  7. Number of participants with device related AEs, SAEs, and device deficiencies

    Time frame: Up to 3 years

Secondary outcomes

  1. Time to first event of ischemic stroke or SE

    Time to first event of ischemic stroke or systemic embolism (SE). Undetermined strokes will be counted as ischemic strokes

    Time frame: Up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2027; primary completion for Dec 2030, 36 months later.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2026
First posted
Jul 31, 2026
StartEst.
Dec 30, 2027
Primary completionEst.
Dec 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07739888
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Dec 30, 2027 (estimated)
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Jul 31, 2026

Study contacts

Anthos Therapeutics a Novartis Company
Contact
novartis.email@novartis.com
1-888-669-6682

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abelacimab

Start the discussion